News & Updates

Denosumab proves better than ibandronate as a sequential therapy in women with postmenopausal osteoporosis who have received romosozumab, as the former yields greater improvements in bone mineral density (BMD) with few severe adverse events, according to the results of the VICTOR study.

Treatment with triheptanoin does not lead to a significant reduction in the frequency of seizures associated with glucose transporter 1 deficiency syndrome (Glut1DS), as shown in a study.

Biologic treatments are effective in the treatment of mucous membrane pemphigoid (MMP), with a good safety profile, except for rituximab, a study has found. However, randomized clinical trials with long-term follow-up are warranted to confirm the safety and efficacy of these agents in MMP patients.

The pan-Janus kinase (JAK) inhibitor delgocitinib in an ointment formulation is well tolerated and demonstrates a dose-response effect in the treatment of patients with chronic hand eczema, according to the results of a phase IIb trial.

The oral FLT3 inhibitor quizartinib more than doubled overall survival (OS) when added to first-line chemotherapy in patients with newly diagnosed FLT3-ITD*-positive acute myeloid leukaemia (AML) in the phase III QuANTUM-First** trial